India Pharma Outlook Team | Thursday, 24 July 2025
Cipla Limited said that it entered into definitive agreements to invest in iCaltech Innovations Private Limited by Optionally Convertible Preference Shares. The deal remains subject to the satisfaction of customary closing conditions.
iCaltech is an Indian-based medical technology company that specializes in the creation of medical diagnostic devices, with a focus on respiratory care. The investment is a complement to Cipla's rich heritage of leadership within the respiratory business and strategic goal of enhancing diagnostic capabilities.
Referring to the expansion, Achin Gupta, Global Chief Operating Officer, Cipla Limited, said, "Being lung leaders, our investment in iCaltech is a testament to Cipla's focus on innovating in respiratory diagnostics. Our strategic investment, with a vision to minimize the current gap in the prevalent ecosystem, will push iCaltech to develop more innovative devices and expand. We are dedicated to making top-quality diagnostic solutions widely accessible throughout India."
Also Read: Indian Pharma Branding Agency Market Outlook, Case Study & More
This investment is consistent with Cipla's persistent efforts to strengthen its respiratory ecosystem via focused partnerships and innovation-driven initiatives. The collaboration will likely enable iCaltech to ramp up its R&D and commercialization initiatives, especially in technologies associated with respiratory diseases for early and effective diagnosis.
Cipla has made sure that it establish a strong portfolio in the inhalation therapy segment, such as devices, medications, and diagnostics. In doing so, the company is reaffirming its intent to provide cost-effective, accessible, and high-quality respiratory solutions for developing markets.
